Recent News

• 09.17.2025 - Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
• 09.16.2025 - Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
• 09.11.2025 - Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
• 09.09.2025 - Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
• 08.14.2025 - Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results
• 07.15.2025 - Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

Recent Filings

• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1